CIC
TEVA icon

Carnegie Investment Counsel’s Teva Pharmaceuticals TEVA Stock Holding History

Carnegie Investment Counsel’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3,800
Closed -$201K – 230
2014
Q1 		$201K Sell
3,800
-6,450
-63% -$298K 0.05% 209
2013
Q4 		$411K Sell
10,250
-7,040
-41% -$277K 0.11% 155
2013
Q3 		$653K Sell
17,290
-7,050
-29% -$275K 0.2% 116
2013
Q2 		$954K Buy
+24,340
New +$948K 0.31% 91

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Carnegie Investment Counsel's TEVA Position: Q2 2014 in Review

Carnegie Investment Counsel sold out of Teva Pharmaceuticals (TEVA) in Q2 2014, closing a stake of 3,800 shares — an estimated $201K sold.

Carnegie Investment Counsel first reported a position in TEVA in Q2 2013 and held it in 4 quarters. The position peaked at $954K in Q2 2013. 780 funds tracked by Wall St. Rank hold TEVA as of Q2 2014.

  • Carnegie Investment Counsel reported no remaining Teva Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Carnegie Investment Counsel sold 3,800 Teva Pharmaceuticals shares in Q2 2014, an estimated $201K.
  • Carnegie Investment Counsel first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Carnegie Investment Counsel's Teva Pharmaceuticals position peaked at $954K in Q2 2013.
  • 780 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2014.

Based on Carnegie Investment Counsel's 13F filing for Q2 2014, filed 12 Aug 2014.